Meta-Analysis

Vaginal dinoprostone versus placebo for pain relief during intrauterine device insertion: a systematic review and meta-analysis of randomized controlled trials

Running title: Dinoprostone vs Placebo for IUD insertion

Ahmed Abu-Zaid^{a,b}, Majed S. Alshahrani^c, Nisreen A. Albezrah^d, Najlaa T. Miski^e, Saud A. Aboudi^f, Mohammed Abuzaid^g, Osama Alomar^{b,h}, Hany Salem^{b,h}, Ismail A. Al-Badawi^{b,h}, Saeed Baradwanⁱ

^a College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

^b Department of Obstetrics and Gynecology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

^c Department of Obstetrics and Gynecology, Faculty of Medicine, Najran University, Najran, Saudi Arabia

^d Department of Obstetrics and Gynecology, Faculty of Medicine, Taif University, Taif, Saudi Arabia

^e Department of Obstetrics and Gynecology, Faculty of Medicine in Rabigh, King Abdulaziz University, Rabigh, Saudi Arabia

^f Department of Obstetrics and Gynecology, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia

^g Department of Obstetrics and Gynecology, King Fahad Medical City, Riyadh, Saudi Arabia

^h Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

ⁱ Department of Obstetrics and Gynecology, HealthPlus Fertility and Women's Health Center, Jeddah, Saudi Arabia

Correspondence address: Ahmed Abu-Zaid, MBBS, PhD (c); Department of Pharmacology, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA; Telephone number: +1(901)-283-4596; Fax number: +1(901)-448-5052; Email address: aabuzaid@live.com; ORCID ID: <https://orcid.org/0000-0003-2286-2181>.

Abstract

Objective: To investigate the safety and efficacy of vaginal dinoprostone versus placebo in pain relief during intrauterine device (IUD) insertion.

Design: Systematic review and meta-analysis of randomized placebo-controlled trials.

Setting: Not applicable.

Patient(s): Women undergoing IUD insertion and receiving vaginal dinoprostone or placebo.

Intervention(s): PubMed, Scopus, Web of Science, and Cochrane Library were screened from inception to 01-October-2020, using the following search strategy: (dinoprostone OR cervidil OR prepidil) AND (intrauterine device OR iud).

Main outcome measure(s): IUD insertion related pain, patient satisfaction, provider ease of IUD insertion, and side effects.

Result(s): Five studies met the study inclusion criteria, comprising 862 patients; equally 431 patients received vaginal dinoprostone and placebo. All studies had an overall low risk of bias. When compared to placebo, dinoprostone significantly correlated with decreased pain at tenaculum placement (SMD=-0.79, 95% CI [-1.43, -0.16], p=0.01), decreased pain at uterine sounding (SMD=-0.88, 95% CI [-1.54, -0.22], p=0.009), decreased pain at IUD insertion (SMD=-1.18, 95% CI [-1.74, -0.61], p<0.001), decreased need for additional analgesia (RR=0.34, 95% CI [0.22, 0.53], p<0.001), increased patient satisfaction (SMD=1.41, 95% CI [0.62, 2.20], p<0.001), and increased provider ease of IUD insertion (SMD=-1.17, 95% CI [-1.62, -0.73], p<0.001). Fever was statistically significantly higher in dinoprostone versus placebo group (RR=3.73, 95% CI [1.47, 9.44], p=0.006). All other side effects—including nausea, vomiting, shivering, diarrhea,

abdominal cramps, vasovagal attack, uterine perforation, and postprocedural bleeding—did not substantially differ between both groups.

Conclusions: This first ever meta-analysis advocates that dinoprostone is safe, effective, and yields favorable analgesic outcomes during IUD insertion.

Keywords: Dinoprostone, placebo, pain relief, intrauterine device

Introduction

Intrauterine devices (IUDs) deliver a largely effective, harmless, and long-lasting method of reversible contraception with an analogous efficacy to tubal sterilization (1, 2). The use of IUDs is highly endorsed by the American College of Obstetricians and Gynecologists (3) and American Academy of Pediatrics (4) to avoid unplanned pregnancies among sexually active adolescents and young women. Globally, the two most frequently utilized IUDs comprise the levonorgestrel-releasing intrauterine system (LNG-IUS) and copper-containing intrauterine device (Cu-IUD) (1, 2), both of which are equally used in nulliparous and multiparous women (5).

There are a few downsides associated with IUD use. Importantly, pain perception is one of the substantial factors contributing to restricted utility of IUDs, particularly among nulliparous women who possess relatively narrower uterine cavities when compared to their multiparous counterparts (6, 7). This remark is in line with the perspective that a large proportion of healthcare personnel restrict IUD administration to nulliparous women owing to worries pertaining to anticipated insertion pain and procedural difficulties (8-10). Indeed, each step of IUD insertion procedure can instigate a large deal of pain perception (11). Therefore, proper control of pain before, during, and after IUD insertion is critically important to favorably maximize the IUD usage frequency and minimize the rate of unplanned pregnancies among sexually active adolescents and young women.

The optimal method of pain relief during IUD insertion remains undefined (12, 13). A contemporary systematic review and network meta-analysis of numerous lines of pharmacologic analgesic interventions—including placebo, nonsteroidal anti-inflammatory drugs, nitric oxide donors, lavender scent, lidocaine, and misoprostol—demonstrated no

tangible effectiveness for IUD insertion-related pain (14). Conversely, lidocaine-prilocaine cream (genital mucosal application) was the most effective intervention for IUD insertion-related pain (14). However, when lidocaine-prilocaine was compared head-to-head with other pharmacologic interventions, including placebo, it did not exhibit significantly reduced pain 5-20 minutes after IUD insertion (14). More research is warranted for alternative analgesics to control pain during IUD insertion procedure.

Dinoprostone is a naturally occurring prostaglandin E2 equivalent (15). It is frequently employed in obstetrics for labor induction, which is mediated through cervical ripening and prompting of uterine contractions with an equivalent labor-inducing efficacy to misoprostol but substantially less adverse events (16). Additionally, dinoprostone has been exploited successfully prior to diagnostic hysteroscopy to ease the procedure and reduce associated pain without considerable toxicity when compared to placebo or misoprostol (17, 18). Only a very limited number of trials examined the safety and efficacy of vaginal dinoprostone versus placebo in facilitating IUD insertion and decreasing its related pain (12, 18-21). To date, no meta-analysis has been conducted to amass the data and inform concrete conclusions. Therefore, the aim of this study is to systematically and meta-analytically synthesize evidence from randomized controlled trials that scrutinized the safety and efficacy of vaginal dinoprostone versus placebo for pain relief among women undergoing IUD insertion.

Methods

This systematic review and meta-analysis was conducted in harmony with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (22).

Literature search strategy

Four databases (PubMed, Scopus, Web of Science, and Cochrane Library) were screened from inception to October 1st, 2020. The following search strategy was used for all databases: (dinoprostone OR cervidil OR prepidil) AND (intrauterine device OR iud). There was no language restriction.

Inclusion and exclusion criteria

We included all articles that met the following criteria for our PICOS evidence-based research question: (I) Patients: women who received LNG-IUS or Cu-IUD for contraception, (II) Intervention: vaginal dinoprostone, (III) Comparator: vaginal placebo, (IV) Outcomes: efficacy and safety endpoints, and (V) Study design: randomized controlled trials. We excluded drugs other than dinoprostone, indications other than contraception, non-randomized study designs, non-human trials, abstracts, and articles without full texts.

Screening of Results

The retrieved citations were exported using EndNote software and duplicates were crossed out. The screening of results was completed through a two-fold phase. The first phase involved title and abstract screening of all citations. The second phase involved retrieval of the full text of all potential citations. Moreover, the reference lists of the included studies were reviewed manually for potential inclusion of other relevant studies. Two authors screened the citations independently and disagreements were resolved by a consensus among the two authors.

Risk of bias assessment of the included studies

We utilized the Cochrane’s risk of bias tool in evaluating the quality of the included studies (23). This tool is elaborated in the Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0, Chapter 8. This tool appraises the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias. Two authors evaluated the risk of bias independently and disagreements were resolved by a consensus among the two authors.

Data Extraction

We extracted three types of data: (I) baseline characteristics of the included studies, (II) efficacy outcomes, and (III) safety outcomes. Data about baseline characteristics of the included studies comprised author’s first name, year of publication, national clinical trial identifier, country, type of IUD device, study group, sample size, timing of drug administration before IUD procedure, and the person administering the drug. Moreover, patients’ age, body mass index, parity, gravidity, position of uterus, history of previous abortion, and history of previous IUD were extracted. Data about efficacy outcomes included pain at tenaculum placement, pain at uterine sounding, pain at IUD insertion, pain after IUD insertion (10-30 mins), need for additional analgesia after procedure, duration of procedure, ease of IUD insertion as reported by healthcare providers, and procedural satisfaction as reported by patients. Pain scores were evaluated according to the 10-cm/100-mm visual analogue scale (VAS) in which “0”

corresponded to no pain at all and “10 cm/100 mm” corresponded to the worst possible pain imaginable. Likewise, ease of IUD insertion as reported by healthcare providers was scored according to a 10-cm/100-mm VAS-like metric in which “0” corresponded to easy insertion and “10 cm/100 mm” corresponded to extremely difficult insertion. Equally, procedural satisfaction as reported by patients was scored according to a 10-cm/100-mm VAS-like metric in which “0” corresponded to no satisfaction and “10 cm/100 mm” corresponded to maximum satisfaction. Data about safety outcomes included nausea, vomiting, diarrhea, shivering, fever, abdominal cramps, postprocedural bleeding, vasovagal attack, and uterine perforation. Four authors participated in data extraction and verification.

Data analysis

Review Manager Software version 5.4 was used for meta-analysis. Continuous data were analyzed using the inverse variance method and reported as weighted mean difference (WMD) or standardized mean difference (SMD), as appropriate, with 95% confidence interval (95% CI). Dichotomous data were analyzed using the Mantel–Haenszel method and reported as risk ratio (RR) with 95% CI. Statistical heterogeneity was established if chi-square was $p < 0.1$ and I-square test (I^2) was $> 50\%$ (24). Fixed- and random-effects models were used for meta-analysis of homogenous and heterogeneous data, respectively. Publication bias was not evaluated since the number of included studies ($n=5$) was lower than the minimum required ($n=10$) (27).

Results

Search results and summary of included studies

Literature search generated a total of 67 studies after omission of duplicated ones. After title and abstract screening, 50 studies were excluded and the remaining 17 studies progressed to full text screening for eligibility. Finally, a total of five (n=5) studies met the inclusion criteria and were included in the qualitative and quantitative synthesis (12, 13, 19-21). **Supplemental Figure 1** displays the PRIMSA flowchart. This meta-analysis included 862 patients; equally 431 patients received vaginal dinoprostone and placebo. All studies originated in Egypt. Three studies included nulliparous women, whereas one study included only patients who delivered by cesarean section. Furthermore, three studies included patients receiving Cu-IUD as the method of contraception. The dose of vaginal dinoprostone was consistent (3 mg) in all studies, however, the duration of drug application differed between studies, ranging from 2 to 12 hours before procedure. Drugs were administered by nurses in three studies and self-administered in two studies. The baseline characteristics of the included studies are displayed in **Supplemental Table 1**.

Risk of bias assessment of the included studies

Overall, the included studies showed an overall low risk of bias. In two studies, the drugs (vaginal dinoprostone and placebo) were self-administered by patients. Although measures had been taken by investigators to remind patients about the time to vaginally self-administer the drugs three (19) and 12 (13) hours before the procedure, however, this cannot be certainly established, and we judged the other bias domain as high risk. The graph and summary of risk of bias are depicted in **Supplemental Figure 2**.

Efficacy outcome: Pain at tenaculum insertion

Three studies were meta-analyzed (12, 13, 19). The overall effect estimate revealed significantly reduced pain at tenaculum insertion in the dinoprostone versus placebo group (SMD=-0.79, 95% CI [-1.43, -0.16], $p=0.01$). Pooled analysis was heterogeneous ($I^2=88\%$, $p=0.0002$) (**Figure 1A**).

Efficacy outcome: Pain at uterine sounding

Three studies were meta-analyzed (12, 13, 19). The overall effect estimate revealed significantly reduced pain at uterine sounding in the dinoprostone versus placebo group (SMD=-0.88, 95% CI [-1.54, -0.22], $p=0.009$). Pooled analysis was heterogeneous ($I^2=89\%$, $p<0.001$) (**Figure 1B**).

Efficacy outcome: Pain at IUD insertion

Five studies were meta-analyzed (12, 13, 19-21). The overall effect estimate revealed significantly reduced pain at IUD insertion in the dinoprostone versus placebo group (SMD=-1.18, 95% CI [-1.74, -0.61], $p<0.001$). Pooled analysis was heterogeneous ($I^2=92\%$, $p<0.001$) (**Figure 1C**).

Efficacy outcome: Pain after IUD insertion (10-30 mins)

Four studies were meta-analyzed (12, 13, 19, 21). The overall effect estimate did not exhibit statistically significant difference between both groups with regard to pain after IUD insertion (SMD=-0.57 [-1.19, 0.05], $p=0.07$). Pooled analysis was heterogeneous ($I^2=92\%$, $p<0.001$) (**Figure 1D**).

Efficacy outcome: Need for additional analgesia

Four studies were meta-analyzed (12, 13, 19, 21). The overall effect estimate revealed significantly reduced need for additional analgesia in the dinoprostone versus placebo group (RR= 0.34, 95% CI [0.22, 0.53], $p<0.001$). Pooled analysis was homogenous ($I^2=0\%$, $p=0.88$) (Figure 2).

Efficacy outcome: Duration of IUD insertion procedure

Five studies were meta-analyzed (12, 13, 19-21). The overall effect estimate did not exhibit statistically significant difference between both groups (MD= - 0.49 [-1.15, 0.18], $p=0.15$). Pooled analysis was heterogeneous ($I^2=96\%$, $p<0.001$) (Supplemental Figure 3).

Efficacy outcome: Patient satisfaction

Four studies were meta-analyzed (12, 13, 19, 21). The overall effect estimate revealed significantly increased patient satisfaction in the dinoprostone versus placebo group (SMD=1.41, 95% CI [0.62, 2.20], $p<0.001$). Pooled analysis was heterogeneous ($I^2=94\%$, $p<0.001$) (Figure 3).

Efficacy outcome: Ease of IUD insertion according to the healthcare provider

Five studies were meta-analyzed (12, 13, 19-21). The overall effect estimate revealed significantly increased ease of IUD insertion in the dinoprostone versus placebo group (SMD=-

1.17, 95% CI [-1.62, -0.73], $p < 0.001$). Pooled analysis was heterogeneous ($I^2 = 88\%$, $p < 0.001$) (Figure 4).

Safety outcomes

Five studies were meta-analyzed (12, 13, 19-21). Frequency of fever was statistically significantly higher in the dinoprostone versus placebo group (RR=3.73, 95% CI [1.47, 9.44], $p = 0.006$). Pooled analysis was homogenous ($I^2 = 0\%$, $p = 0.92$). All other side effects—including nausea (RR=1.03, 95% CI [0.69, 1.53], $p = 0.90$), vomiting (RR=2.11, 95% CI [0.97, 4.61], $p = 0.06$), diarrhea (RR=2.78, 95% CI [0.95, 8.09], $p = 0.06$), shivering (RR=2.38, 95% CI [0.96, 5.90], $p = 0.06$), abdominal cramps (RR=1.76, 95% CI [0.73, 4.26], $p = 0.21$), and postprocedural bleeding (RR=1.02, 95% CI [0.92, 1.14], $p = 0.72$)—did not substantially differ between both groups. Pooled analyses were homogenous for all side effects ($I^2 = 0\%$), except abdominal cramps; pooled analysis was heterogeneous ($I^2 = 85\%$, $p < 0.001$). No cases of vasovagal attack or uterine perforation happened in either group (Supplemental File 1).

Discussion

This systematic review and meta-analysis endeavored to examine the safety and efficacy of vaginal dinoprostone versus placebo in controlling pain during IUD insertion. We included five high quality randomized controlled trials comprising 862 patients (dinoprostone, $n = 431$ and placebo, $n = 431$).

Despite IUD insertion is relatively a quick (5-10 minutes) procedure, each step of it can bring about variable extents of pain (11). Sources of pain comprise speculum insertion,

tenaculum placement, transcervical sounding of uterus, forward advancement of IUD inserter into uterine cavity, and postprocedural pain. When compared to placebo, our pooled analyses showed that dinoprostone significantly reduced pain at tenaculum placement, transcervical sounding of uterus, and IUD insertion. This clinically meaningful pain reduction was positively correlated with increased patient-reported procedural satisfaction and decreased requirement for additional postprocedural analgesia. Nonetheless, although pain after IUD insertion was reduced, this pain reduction did not reach statistical significance. The lack of statistically significant pain reduction after IUD insertion could be credited to the variable time points that were used to assess this parameter across all the pooled four studies (10, 15, 20, and 30 min).

Our findings indicated that dinoprostone was correlated with significantly increased ease of IUD insertion by healthcare providers. Nonetheless, the IUD insertion time was not substantially impacted. This increased ease of insertion score could be ascribed to the favorable cervical ripening effects of dinoprostone (15, 28). Mechanistically, dinoprostone initiates cervical softening through stimulation of interleukin 8 (IL-8), which in turn facilitates influx of polymorphonuclear leukocyte neutrophils that orchestrate remodeling of cervical extracellular matrix and induction of progesterone withdrawal (28).

There are some risk factors that may subscribe to more severe pain perception during IUD insertion. Such factors comprise nulliparity, women who delivered only by cesarean section, and use of LNG-IUS (25, 26, 29). When compared to parous women, nulliparous women relatively possess narrower uterine cavities which may not properly fit the dimensions of conventional IUDs, thus culminating in higher IUD insertion pain (7). Moreover, while a history of cesarean section does not automatically preclude IUD insertion, nevertheless, a structurally

disfigured uterus secondary to repetitive cesarean section may potentially correlate with difficult IUD insertion and discomfort (30). Lastly, the comparatively thicker diameter of LNG-IUS inserter (ranging from 4.65 to 4.85 mm) contrasted to Cu-IUD counterpart (around 4.0 mm) may cause more pain during insertion (29). In our study, subgroup analyses according to parity and device of contraception (data not shown) revealed that dinoprostone equally significantly correlated with better pain control, patient satisfaction, and ease of IUD insertion during the procedure when compared to placebo. This study suggests that dinoprostone can yield successful insertion of IUD in both nulliparous and parous women with favorable efficacy outcomes.

Our summary data depicted that side effects did not significantly differ between dinoprostone and placebo groups. Fever was the only drug-related side effect that was significantly higher in the dinoprostone group when compared to placebo group. This side effect is, to a larger degree, expected as the association between prostaglandin E2 and occurrence of fever is well documented in literature (31). Other than fever which can be adequately and conservatively managed by antipyretics, our study suggests dinoprostone is highly effective and associated with satisfactory safety profile.

Dinoprostone is widely used for the obstetric indication of labor induction owing to favorable cervical softening and uterine contractility properties (15, 28). A meta-analysis demonstrated that while dinoprostone is efficaciously equivalent to misoprostol in labor induction, it is associated with better toxicity profile, particularly in terms of lower frequencies of tachysystole and hypertonic uterine dysfunction (16). Also, use of dinoprostone has been extended to non-obstetric indications such as hysteroscopy in nulliparous (17) and

postmenopausal (18) women and correlated with better pain control and ease of procedure when compared to placebo or misoprostol. This study further supports the clinical utility of dinoprostone in an additional non-obstetric indication—that is, during IUD insertion to control procedure-related pain and facilitate its ease of conduction.

The optimal method of pain relief during IUD insertion remains undefined (12, 13). A contemporary systematic review and network meta-analysis of numerous lines of pharmacologic analgesic interventions showed that lidocaine-prilocaine cream (genital mucosal application) was the most effective intervention for controlling IUD insertion-related pain (14). Dinoprostone was not included in the aforementioned network meta-analysis. Thus, future research should be geared toward direct comparison of efficacy and safety of vaginal dinoprostone versus lidocaine-prilocaine cream (and other active comparators such as misoprostol, lidocaine, and nonsteroidal anti-inflammatory drugs) in controlling pain associated with IUD insertion. This should be achieved through development of well-designed randomized controlled trials that take into account women who are at high risk for more painful experiences, such as nulliparous women, women who delivered only by cesarean section, women who failed previous insertions, and women who will receive the comparatively thicker LNG-IUS (as opposed to Cu-IUD) devices.

Dinoprostone possesses two major drawbacks that ought to be acknowledged. First, from a financial perspective, it is costly when compared to its closely related comparator misoprostol (32, 33). Second, from a physiochemical perspective, it is unstable at room temperature and should be stored in freezer/refrigerator until before use to preserve its potency (12).

This study has several strengths. First, this is the first systematic review and meta-analysis that pooled the efficacy and safety of vaginal dinoprostone versus placebo in controlling pain during IUD insertion. We included only randomized placebo-controlled trials (n=5) to lessen potentials of bias and confounding in our pooled conclusions. All included studies were of high quality and low risk of bias. We strictly adhered to PRISMA guidelines during the conduction of this research. Moreover, we reported many efficacy and safety endpoints. All in all, our study suggests the beneficial role of vaginal dinoprostone for a non-obstetric indication, which is controlling pain during IUD insertion. Nonetheless, this study has some limitations that should be recognized. Such limitations comprise the subjective evaluation of pain which may be impacted by the patients' sociodemographics or pre-anxiety levels. The studies varied substantially with regard to timing of vaginal dinoprostone administration, ranging from two to 12 hours prior to IUD insertion, as well as timing of assessing pain after IUD insertion, ranging from 10 to 30 mins. All these variations could have negatively impacted the factual assessment of the efficacy endpoint. Importantly, the optimal timing of dinoprostone administration is yet to be determined. Lastly, all the included studies originated from one country/institute, thus relatively limiting the generalizability of the outcomes.

Conclusions

This systematic review and meta-analysis suggests that vaginal dinoprostone is correlated with increased ease of insertion by providers, higher satisfaction by patients, and decreased IUD insertion-related pain. Moreover, dinoprostone is largely safe with very tolerable toxicity profile. All in all, this study supports the clinical utility of vaginal dinoprostone for pain relief

during IUD insertion, including those nulliparas who are at high risk for increased pain perception.

Acknowledgement: None

Funding: None

Conflict of interest: None

References

1. Buhling KJ, Zite NB, Lotke P, Black K, Group IW. Worldwide use of intrauterine contraception: a review. *Contraception* 2014;89:162–73.
2. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. *N Engl J Med* 2012;366:1998–2007.
3. Committee on Practice Bulletins-Gynecology Ln-ARCWG. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. *Obstet Gynecol* 2017;130:e251–69.
4. Committee on Adolescence. Contraception for adolescents. *Pediatrics* 2014;134:e1244–56.
5. Tassi A, Parisi N, Londero AP. Misoprostol administration prior to intrauterine contraceptive device insertion: a systematic review and meta-analysis of randomised controlled trials. *Eur J Contracept Reprod Health Care* 2020;25:76–86.
6. Brown WM, Trouton K. Intrauterine device insertions: which variables matter? *J Fam Plann Reprod Health Care* 2014;40:117–21.
7. Wildemeersch D, Hasskamp T, Nolte K, Jandi S, Pett A, Linden S, et al. A multicenter study assessing uterine cavity width in over 400 nulliparous women seeking IUD insertion using 2D and 3D sonography. *Eur J Obstet Gynecol Reprod Biol* 2016;206:232–8.
8. Lyus R, Lohr P, Prager S, Planning BotSoF. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. *Contraception* 2010;81:367–71.
9. Buhling KJ, Hauck B, Dermout S, Ardaens K, Marions L. Understanding the barriers and myths limiting the use of intrauterine contraception in nulliparous women: results of a

- survey of European/Canadian healthcare providers. *Eur J Obstet Gynecol Reprod Biol* 2014;183:146–54.
10. Luchowski AT, Anderson BL, Power ML, Raglan GB, Espey E, Schulkin J. Obstetrician-gynecologists and contraception: practice and opinions about the use of IUDs in nulliparous women, adolescents and other patient populations. *Contraception* 2014;89:572–7.
11. Abbas AM, Abdellah MS, Khalaf M, Bahloul M, Abdellah NH, Ali MK, et al. Effect of cervical lidocaine-prilocaine cream on pain perception during copper T380A intrauterine device insertion among parous women: A randomized double-blind controlled trial. *Contraception* 2017;95:251–6.
12. Ashour ASA, El Sharkawy M, Ali AS, Keshta NHA, Shatat HBAE, El Mahy M. Comparative Efficacy of Vaginal Misoprostol vs Vaginal Dinoprostone Administered 3 Hours Prior to Copper T380A Intrauterine Device Insertion in Nulliparous Women: A Randomized Controlled Trial. *J Pediatr Adolesc Gynecol* 2020;33:559–65.
13. Samy A, Ali AS, Latif D, Darweesh FF, Ghamry NK, Metwally AA. Benefits of Self-administered Vaginal Dinoprostone 12 Hours before Levonorgestrel-releasing Intrauterine Device Insertion in Nulliparous Adolescents and Young Women: A Randomized Controlled Trial. *J Pediatr Adolesc Gynecol* 2020;33:382–7.
14. Samy A, Abbas AM, Mahmoud M, Taher A, Awad MH, El Hussein T, et al. Evaluating different pain lowering medications during intrauterine device insertion: a systematic review and network meta-analysis. *Fertil Steril* 2019;111:553–61.e4.
15. Shirley M. Dinoprostone Vaginal Insert: A Review in Cervical Ripening. *Drugs* 2018;78):1615–24.

16. Liu A, Lv J, Hu Y, Lang J, Ma L, Chen W. Efficacy and safety of intravaginal misoprostol versus intracervical dinoprostone for labor induction at term: a systematic review and meta-analysis. *J Obstet Gynaecol Res* 2014;40:897–906.
17. Inal HA, Ozturk Inal ZH, Tonguc E, Var T. Comparison of vaginal misoprostol and dinoprostone for cervical ripening before diagnostic hysteroscopy in nulliparous women. *Fertil Steril* 2015;103:1326–31.
18. Samy A, Abbas AM, Rashwan A, Talaat B, Eissa AI, Metwally AA, et al. Vaginal Dinoprostone in Reducing Pain Perception During Diagnostic Office Hysteroscopy in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Trial. *J Minim Invasive Gynecol* 2020;27:847–53.
19. Ashour AS, Nabil H, Yosif MF, Hussein M, Mageed A Allah AA, Mahmoud M, et al. Effect of self-administered vaginal dinoprostone on pain perception during copper intrauterine device insertion in parous women: a randomized controlled trial. *Fertil Steril* 2020 Jul 27;S0015-0282(20)30439-8. doi: 10.1016/j.fertnstert.2020.05.004.
20. Samy A, Kasem MFY, El Lithy A, Ibrahim AM, El Mahy M, Hussein AH, et al. Prophylactic vaginal dinoprostone administration six hours prior to copper-T380A intrauterine device insertion in nulliparous women: A randomized controlled trial. *Contraception* 2020;101:162–6.
21. Samy A, Abdelhakim AM, Latif D, Hamza M, Osman OM, Metwally AA. Benefits of vaginal dinoprostone administration prior to levonorgestrel-releasing intrauterine system insertion in women delivered only by elective cesarean section: a randomized double-blinded clinical trial. *Arch Gynecol Obstet* 2020;301:1463–71.

22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
23. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *Bmj* 2011;343:d5928.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Bmj* 2003;327:557–60.
25. Ireland LD, Allen RH. Pain Management for Gynecologic Procedures in the Office. *Obstet Gynecol Surv.* 2016;71:89–98.
26. Kass-Wolff JH, Fisher JE. Evidence-based pain management for endometrial biopsies and IUD insertions. *Nurse Pract* 2014;39:43–50.
27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj* 1997;315:629–34.
28. Bakker R, Pierce S, Myers D. The role of prostaglandins E1 and E2, dinoprostone, and misoprostol in cervical ripening and the induction of labor: a mechanistic approach. *Arch Gynecol Obstet* 2017;296:167–79.
29. Kaislasuo J, Heikinheimo O, Lähteenmäki P, Suhonen S. Predicting painful or difficult intrauterine device insertion in nulligravid women. *Obstet Gynecol* 2014;124:345–53.
30. Santos AR, Bahamondes MV, Hidalgo MM, Atti A, Bahamondes L, Monteiro I. Pain at insertion of the levonorgestrel-releasing intrauterine system in nulligravida and parous women with and without cesarean section. *Contraception* 2013;88:164–8.
31. Coceani F, Bishai I, Lees J, Sirko S. Prostaglandin E2 and fever: a continuing debate. *Yale J Biol Med* 1986;59:169–74.

32. Nadia Bennett K, Park H, Cioffi J, Calixte R, Vintzileos A. A comparison of obstetrical outcomes and costs between misoprostol and dinoprostone for induction of labor. *J Matern Fetal Neonatal Med* 2016;29:3732-6.
33. Ramsey PS, Harris DY, Ogburn PL, Jr., Heise RH, Magtibay PM, Ramin KD. Comparative efficacy and cost of the prostaglandin analogs dinoprostone and misoprostol as labor preinduction agents. *Am J Obstet Gynecol* 2003;188:560–5.

Figure Legends

Figure 1. Forest plot showing the effect size for (A) pain at tenaculum insertion, (B) pain at uterine sounding, (C) pain at intrauterine device (IUD) insertion, and (D) pain after IUD insertion (10-30 mins) between vaginal dinoprostone and placebo groups.

Figure 2. Forest plot showing the effect size for need for additional analgesia after intrauterine device (IUD) insertion between vaginal dinoprostone and placebo groups.

Figure 3. Forest plot showing the effect size for patient satisfaction between vaginal dinoprostone and placebo groups.

Figure 4. Forest plot showing provider ease of insertion of intrauterine device (IUD) between vaginal dinoprostone and placebo groups.

Supplemental Tables

Supplemental Table 1. Baseline characteristics of the included studies.

Supplemental Figures

Supplemental Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart.

Supplemental Figure 2. Risk of bias summary and graph.

Supplemental Figure 3. Forest plot showing the effect size for duration of intrauterine device (IUD) insertion between vaginal dinoprostone and placebo groups.

Supplemental Files

Supplemental File 1. Forest plots showing the effect sizes for side effects between vaginal dinoprostone and placebo groups.

A **B** **C** **D**

	Development Phase		Production		Phase 1 Status		Phase 2 Status	
Development Phases	1 month	2 month	1 month	2 month	3 month	4 month	5 month	6 month
Dev Phase 1 (2023-01-01)	1	2	1	2	3	4	5	6
Dev Phase 2 (2023-02-01)		3	2	3	4	5	6	7
Testing Phase 1 (2023-03-01)	2	3	3	4	5	6	7	8
Testing Phase 2 (2023-04-01)		4	4	5	6	7	8	9
Total Phase 1 Exp	2000		2000		2000		2000	
Dev Phase 3 (2023-05-01)	3	4	3	4	5	6	7	8
Dev Phase 4 (2023-06-01)		5	4	5	6	7	8	9
Testing Phase 3 (2023-07-01)	4	5	5	6	7	8	9	10
Testing Phase 4 (2023-08-01)		6	6	7	8	9	10	11
Total Phase 2 Exp	2000		2000		2000		2000	
Dev Phase 5 (2023-09-01)	5	6	5	6	7	8	9	10
Dev Phase 6 (2023-10-01)		7	6	7	8	9	10	11
Testing Phase 5 (2023-11-01)	6	7	7	8	9	10	11	12
Testing Phase 6 (2023-12-01)		8	8	9	10	11	12	13
Total Phase 3 Exp	2000		2000		2000		2000	
Dev Phase 7 (2024-01-01)	7	8	7	8	9	10	11	12
Dev Phase 8 (2024-02-01)		9	8	9	10	11	12	13
Testing Phase 7 (2024-03-01)	8	9	9	10	11	12	13	14
Testing Phase 8 (2024-04-01)		10	10	11	12	13	14	15
Total Phase 4 Exp	2000		2000		2000		2000	
Dev Phase 9 (2024-05-01)	9	10	9	10	11	12	13	14
Dev Phase 10 (2024-06-01)		11	10	11	12	13	14	15
Testing Phase 9 (2024-07-01)	10	11	11	12	13	14	15	16
Testing Phase 10 (2024-08-01)		12	12	13	14	15	16	17
Total Phase 5 Exp	2000		2000		2000		2000	
Dev Phase 11 (2024-09-01)	11	12	11	12	13	14	15	16
Dev Phase 12 (2024-10-01)		13	12	13	14	15	16	17
Testing Phase 11 (2024-11-01)	12	13	13	14	15	16	17	18
Testing Phase 12 (2024-12-01)		14	14	15	16	17	18	19
Total Phase 6 Exp	2000		2000		2000		2000	
Dev Phase 13 (2025-01-01)	13	14	13	14	15	16	17	18
Dev Phase 14 (2025-02-01)		15	14	15	16	17	18	19
Testing Phase 13 (2025-03-01)	14	15	15	16	17	18	19	20
Testing Phase 14 (2025-04-01)		16	16	17	18	19	20	21
Total Phase 7 Exp	2000		2000		2000		2000	
Dev Phase 15 (2025-05-01)	15	16	15	16	17	18	19	20
Dev Phase 16 (2025-06-01)		17	16	17	18	19	20	21
Testing Phase 15 (2025-07-01)	16	17	17	18	19	20	21	22
Testing Phase 16 (2025-08-01)		18	18	19	20	21	22	23
Total Phase 8 Exp	2000		2000		2000		2000	
Dev Phase 17 (2025-09-01)	17	18	17	18	19	20	21	22
Dev Phase 18 (2025-10-01)		19	18	19	20	21	22	23
Testing Phase 17 (2025-11-01)	18	19	19	20	21	22	23	24
Testing Phase 18 (2025-12-01)		20	20	21	22	23	24	25
Total Phase 9 Exp	2000		2000		2000		2000	
Dev Phase 19 (2026-01-01)	19	20	19	20	21	22	23	24
Dev Phase 20 (2026-02-01)		21	20	21	22	23	24	25
Testing Phase 19 (2026-03-01)	20	21	21	22	23	24	25	26
Testing Phase 20 (2026-04-01)		22	22	23	24	25	26	27
Total Phase 10 Exp	2000		2000		2000		2000	
Dev Phase 21 (2026-05-01)	21	22	21	22	23	24	25	26
Dev Phase 22 (2026-06-01)		23	22	23	24	25	26	27
Testing Phase 21 (2026-07-01)	22	23	23	24	25	26	27	28
Testing Phase 22 (2026-08-01)		24	24	25	26	27	28	29
Total Phase 11 Exp	2000		2000		2000		2000	
Dev Phase 23 (2026-09-01)	23	24	23	24	25	26	27	28
Dev Phase 24 (2026-10-01)		25	24	25	26	27	28	29
Testing Phase 23 (2026-11-01)	24	25	25	26	27	28	29	30
Testing Phase 24 (2026-12-01)		26	26	27	28	29	30	31
Total Phase 12 Exp	2000		2000		2000		2000	
Dev Phase 25 (2027-01-01)	25	26	25	26	27	28	29	30
Dev Phase 26 (2027-02-01)		27	26	27	28	29	30	31
Testing Phase 25 (2027-03-01)	26	27	27	28	29	30	31	32
Testing Phase 26 (2027-04-01)		28	28	29	30	31	32	33
Total Phase 13 Exp	2000		2000		2000		2000	
Dev Phase 27 (2027-05-01)	27	28	27	28	29	30	31	32
Dev Phase 28 (2027-06-01)		29	28	29	30	31	32	33
Testing Phase 27 (2027-07-01)	28	29	29	30	31	32	33	34
Testing Phase 28 (2027-08-01)		30	30	31	32	33	34	35
Total Phase 14 Exp	2000		2000		2000		2000	
Dev Phase 29 (2027-09-01)	29	30	29	30	31	32	33	34
Dev Phase 30 (2027-10-01)		31	30	31	32	33	34	35
Testing Phase 29 (2027-11-01)	30	31	31	32	33	34	35	36
Testing Phase 30 (2027-12-01)		32	32	33	34	35	36	37
Total Phase 15 Exp	2000		2000		2000		2000	
Dev Phase 31 (2028-01-01)	31	32	31	32	33	34	35	36
Dev Phase 32 (2028-02-01)		33	32	33	34	35	36	37
Testing Phase 31 (2028-03-01)	32	33	33	34	35	36	37	38
Testing Phase 32 (2028-04-01)		34	34	35	36	37	38	39
Total Phase 16 Exp	2000		2000		2000		2000	
Dev Phase 33 (2028-05-01)	33	34	33	34	35	36	37	38
Dev Phase 34 (2028-06-01)		35	34	35	36	37	38	39
Testing Phase 33 (2028-07-01)	34	35	35	36	37	38	39	40
Testing Phase 34 (2028-08-01)		36	36	37	38	39	40	41
Total Phase 17 Exp	2000		2000		2000		2000	
Dev Phase 35 (2028-09-01)	35	36	35	36	37	38	39	40
Dev Phase 36 (2028-10-01)		37	36	37	38	39	40	41
Testing Phase 35 (2028-11-01)	36	37	37	38	39	40	41	42
Testing Phase 36 (2028-12-01)		38	38	39	40	41	42	43
Total Phase 18 Exp	2000		2000		2000		2000	
Dev Phase 37 (2029-01-01)	37	38	37	38	39	40	41	42
Dev Phase 38 (2029-02-01)		39	38	39	40	41	42	43
Testing Phase 37 (2029-03-01)	38	39	39	40	41	42	43	44
Testing Phase 38 (2029-04-01)		40	40	41	42	43	44	45
Total Phase 19 Exp	2000		2000		2000		2000	
Dev Phase 39 (2029-05-01)	39	40	39	40	41	42	43	44
Dev Phase 40 (2029-06-01)		41	40	41	42	43	44	45
Testing Phase 39 (2029-07-01)	40	41	41	42	43	44	45	46
Testing Phase 40 (2029-08-01)		42	42	43	44	45	46	47
Total Phase 20 Exp	2000		2000		2000		2000	
Dev Phase 41 (2029-09-01)	41	42	41	42	43	44	45	46
Dev Phase 42 (2029-10-01)		43	42	43	44	45	46	47
Testing Phase 41 (2029-11-01)	42	43	43	44	45	46	47	48
Testing Phase 42 (2029-12-01)		44	44	45	46	47	48	49
Total Phase 21 Exp	2000		2000		2000		2000	
Dev Phase 43 (2030-01-01)	43	44	43	44	45	46	47	48
Dev Phase 44 (2030-02-01)		45	44	45	46	47	48	49
Testing Phase 43 (2030-03-01)	44	45	45	46	47	48	49	50
Testing Phase 44 (2030-04-01)		46	46	47	48	49	50	51
Total Phase 22 Exp	2000		2000		2000		2000	
Dev Phase 45 (2030-05-01)	45	46	45	46	47	48	49	50
Dev Phase 46 (2030-06-01)		47	46	47	48	49	50	51
Testing Phase 45 (2030-07-01)	46	47	47	48	49	50	51	52
Testing Phase 46 (2030-08-01)		48	48	49	50	51	52	53
Total Phase 23 Exp	2000		2000		2000		2000	
Dev Phase 47 (2030-09-01)	47	48	47	48	49	50	51	52
Dev Phase 48 (2030-10-01)		49	48	49	50	51	52	53
Testing Phase 47 (2030-11-01)	48	49	49	50	51	52	53	54
Testing Phase 48 (2030-12-01)		50	50	51	52	53	54	55
Total Phase 24 Exp	2000		2000		2000		2000	
Dev Phase 49 (2031-01-01)	49	50	49	50	51	52	53	54
Dev Phase 50 (2031-02-01)		51	50	51	52	53	54	55
Testing Phase 49 (2031-03-01)	50	51	51	52	53	54	55	56
Testing Phase 50 (2031-04-01)		52	52	53	54	55	56	57
Total Phase 25 Exp	2000		2000		2000		2000	
Dev Phase 51 (2031-05-01)	51	52	51	52	53	54	55	56
Dev Phase 52 (2031-06-01)		53	52	53	54	55	56	57
Testing Phase 51 (2031-07-01)	52	53	53	54	55	56	57	58
Testing Phase 52 (2031-08-01)		54	54	55	56	57	58	59
Total Phase 26 Exp	2000		2000		2			

Category and Subcategory	Management Issues			Performance			Total Revenue Performance			Net Revenue Performance		
	Revenue	Cost	Profit	Revenue	Cost	Profit	Rev. Performance, 2023-24	Cost Performance, 2023-24	Net Performance, 2023-24	Rev. Performance, 2024-25	Cost Performance, 2024-25	Net Performance, 2024-25
Category A	100	50	50	100	50	50	100%	50%	50%	100%	50%	50%
Category B	200	100	100	200	100	100	200%	100%	100%	200%	100%	100%
Category C	300	150	150	300	150	150	300%	150%	150%	300%	150%	150%
Category D	400	200	200	400	200	200	400%	200%	200%	400%	200%	200%
Category E	500	250	250	500	250	250	500%	250%	250%	500%	250%	250%
Category F	600	300	300	600	300	300	600%	300%	300%	600%	300%	300%
Category G	700	350	350	700	350	350	700%	350%	350%	700%	350%	350%
Category H	800	400	400	800	400	400	800%	400%	400%	800%	400%	400%
Category I	900	450	450	900	450	450	900%	450%	450%	900%	450%	450%
Category J	1000	500	500	1000	500	500	1000%	500%	500%	1000%	500%	500%
Category K	1100	550	550	1100	550	550	1100%	550%	550%	1100%	550%	550%
Category L	1200	600	600	1200	600	600	1200%	600%	600%	1200%	600%	600%
Category M	1300	650	650	1300	650	650	1300%	650%	650%	1300%	650%	650%
Category N	1400	700	700	1400	700	700	1400%	700%	700%	1400%	700%	700%
Category O	1500	750	750	1500	750	750	1500%	750%	750%	1500%	750%	750%
Category P	1600	800	800	1600	800	800	1600%	800%	800%	1600%	800%	800%
Category Q	1700	850	850	1700	850	850	1700%	850%	850%	1700%	850%	850%
Category R	1800	900	900	1800	900	900	1800%	900%	900%	1800%	900%	900%
Category S	1900	950	950	1900	950	950	1900%	950%	950%	1900%	950%	950%
Category T	2000	1000	1000	2000	1000	1000	2000%	1000%	1000%	2000%	1000%	1000%
Category U	2100	1050	1050	2100	1050	1050	2100%	1050%	1050%	2100%	1050%	1050%
Category V	2200	1100	1100	2200	1100	1100	2200%	1100%	1100%	2200%	1100%	1100%
Category W	2300	1150	1150	2300	1150	1150	2300%	1150%	1150%	2300%	1150%	1150%
Category X	2400	1200	1200	2400	1200	1200	2400%	1200%	1200%	2400%	1200%	1200%
Category Y	2500	1250	1250	2500	1250	1250	2500%	1250%	1250%	2500%	1250%	1250%
Category Z	2600	1300	1300	2600	1300	1300	2600%	1300%	1300%	2600%	1300%	1300%
Category AA	2700	1350	1350	2700	1350	1350	2700%	1350%	1350%	2700%	1350%	1350%
Category AB	2800	1400	1400	2800	1400	1400	2800%	1400%	1400%	2800%	1400%	1400%
Category AC	2900	1450	1450	2900	1450	1450	2900%	1450%	1450%	2900%	1450%	1450%
Category AD	3000	1500	1500	3000	1500	1500	3000%	1500%	1500%	3000%	1500%	1500%
Category AE	3100	1550	1550	3100	1550	1550	3100%	1550%	1550%	3100%	1550%	1550%
Category AF	3200	1600	1600	3200	1600	1600	3200%	1600%	1600%	3200%	1600%	1600%
Category AG	3300	1650	1650	3300	1650	1650	3300%	1650%	1650%	3300%	1650%	1650%
Category AH	3400	1700	1700	3400	1700	1700	3400%	1700%	1700%	3400%	1700%	1700%
Category AI	3500	1750	1750	3500	1750	1750	3500%	1750%	1750%	3500%	1750%	1750%
Category AJ	3600	1800	1800	3600	1800	1800	3600%	1800%	1800%	3600%	1800%	1800%
Category AK	3700	1850	1850	3700	1850	1850	3700%	1850%	1850%	3700%	1850%	1850%
Category AL	3800	1900	1900	3800	1900	1900	3800%	1900%	1900%	3800%	1900%	1900%
Category AM	3900	1950	1950	3900	1950	1950	3900%	1950%	1950%	3900%	1950%	1950%
Category AN	4000	2000	2000	4000	2000	2000	4000%	2000%	2000%	4000%	2000%	2000%
Category AO	4100	2050	2050	4100	2050	2050	4100%	2050%	2050%	4100%	2050%	2050%
Category AP	4200	2100	2100	4200	2100	2100	4200%	2100%	2100%	4200%	2100%	2100%
Category AQ	4300	2150	2150	4300	2150	2150	4300%	2150%	2150%	4300%	2150%	2150%
Category AR	4400	2200	2200	4400	2200	2200	4400%	2200%	2200%	4400%	2200%	2200%
Category AS	4500	2250	2250	4500	2250	2250	4500%	2250%	2250%	4500%	2250%	2250%
Category AT	4600	2300	2300	4600	2300	2300	4600%	2300%	2300%	4600%	2300%	2300%
Category AU	4700	2350	2350	4700	2350	2350	4700%	2350%	2350%	4700%	2350%	2350%
Category AV	4800	2400	2400	4800	2400	2400	4800%	2400%	2400%	4800%	2400%	2400%
Category AW	4900	2450	2450	4900	2450	2450	4900%	2450%	2450%	4900%	2450%	2450%
Category AX	5000	2500	2500	5000	2500	2500	5000%	2500%	2500%	5000%	2500%	2500%
Category AY	5100	2550	2550	5100	2550	2550	5100%	2550%	2550%	5100%	2550%	2550%
Category AZ	5200	2600	2600	5200	2600	2600	5200%	2600%	2600%	5200%	2600%	2600%
Category BA	5300	2650	2650	5300	2650	2650	5300%	2650%	2650%	5300%	2650%	2650%
Category BB	5400	2700	2700	5400	2700	2700	5400%	2700%	2700%	5400%	2700%	2700%
Category BC	5500	2750	2750	5500	2750	2750	5500%	2750%	2750%	5500%	2750%	2750%
Category BD	5600	2800	2800	5600	2800	2800	5600%	2800%	2800%	5600%	2800%	2800%
Category BE	5700	2850	2850	5700	2850	2850	5700%	2850%	2850%	5700%	2850%	2850%
Category BF	5800	2900	2900	5800	2900	2900	5800%	2900%	2900%	5800%	2900%	2900%
Category BG	5900	2950	2950	5900	2950	2950	5900%	2950%	2950%	5900%	2950%	2950%
Category BH	6000	3000	3000	6000	3000	3000	6000%	3000%	3000%	6000%	3000%	3000%
Category BI	6100	3050	3050	6100	3050	3050	6100%	3050%	3050%	6100%	3050%	3050%
Category BJ	6200	3100	3100	6200	3100	3100	6200%	3100%	3100%	6200%	3100%	3100%
Category BK	6300	3150	3150	6300	3150	3150	6300%	3150%	3150%	6300%	3150%	3150%
Category BL	6400	3200	3200	6400	3200	3200	6400%	3200%	3200%	6400%	3200%	3200%
Category BM	6500	3250	3250	6500	3250	3250	6500%	3250%	3250%	6500%	3250%	3250%
Category BN	6600	3300	3300	6600	3300	3300	6600%	3300%	3300%	6600%	3300%	3300%
Category BO	6700	3350	3350	6700	3350	3350	6700%	3350%	3350%	6700%	3350%	3350%
Category BP	6800	3400	3400	6800	3400	3400	6800%	3400%	3400%	6800%	3400%	3400%
Category BQ	6900	3450	3450	6900	3450	3450	6900%	3450%	3450%	6900%	3450%	3450%
Category BR	7000	3500	3500	7000	3500	3500	7000%	3500%	3500%	7000%	3500%	3500%
Category BS	7100	3550	3550	7100	3550	3550	7100%	3550%	3550%	7100%	3550%	3550%
Category BT	7200	3600	3600	7200	3600	3600	7200%	3600%	3600%	7200%	3600%	3600%
Category BU	7300	3650	3650	7300	3650	3650	7300%	3650%	3650%	7300%	3650%	3650%
Category BV	7400	3700	3700	7400	3700	3700	7400%	3700%	3700%	7400%	3700%	3700%
Category BW	7500	3750	3750	7500	3750	3750	7500%	3750%	3750%	7500%	3750%	3750%
Category BX	7600	3800	3800	7600	3800	3800	7600%	3800%	3800%	7600%	3800%	3800%
Category BY	7700	3850	3850	7700	3850	3850	7700%	3850%	3850%	7700%	3850%	3850%
Category BZ	7800	3900	3900	7800	3900	3900	7800%	3900%	3900%	7800%	3900%	3900%
Category CA	7900	3950	3950	7900	3950	3950	7900%	3950%	3950%	7900%	3950%	3950%
Category CB	8000	4000	4000	8000	4000	4000	8000%	4000%	4000%	8000%	4000%	4000%
Category CC	8100	4050	4050	8100	4050	4050	8100%	4050%	4050%	8100%	4050%	4050%
Category CD	8200	4100	4100	8200	4100	4100	8200%	4100%	4100%	8200%	4100%	4100%
Category CE	8300	4150	4150	8300	4150	4150	8300%	4150%	4150%	8300%	4150%	4150%
Category CF	8400	4200	4200	8400	4200	4200	8400%	4200%	4200%	8400%	4200%	4200%
Category CG	8500	4250	4250	8500	4250	4250	8500%	4250%	4250%	8500%	4250%	4250%
Category CH	8600	4300	4300	8600	4300	4300	8600%	4300%	4300%	8600%	4300%	4300%
Category CI	8700	4350	4350	8700	4350	4350	8700%	4350%	4350%	8700%	4350%	4350%
Category CJ	8800	4400	4400	8800	4400	4400	8800%	4400%	4400%	8800%	4400%	4400%
Category CK	8900	4450	4450	8900	4450	4450	8900%	4450%	4450%	8900%	4450%	4450%
Category CL	9000	4500	4500	9000	4500	4500	9000%	4500%	4500%	9000%	4500%	4500%
Category CM	9100	4550	4550	9100	4550	4550	9100%	4550%	4550%	9100%	4550%	4550%
Category CN	9200	4600	4600	9200	4600	4600	9200%	4600%	4600%	9200%	4600%	4600%
Category CO	9300	4650	4650	9300	4650	4650	9300%	4650%	4650%	9300%	4650%	4650%
Category CP	9400	4700	4700	9400	4700	4700	9400%	4700%	4700%	9400%	4700%	4700%
Category CQ	9500	4750	4750	9500	4750	4750	9500%	4750%	4750%	9500%	4750%	4750%
Category CR	9600	4800	4800	9600	4800	4800	9600%	4800%	4800%	9600%	4800%	4800%
Category CS	9700	4850	4850	9700	4850	4850	9700%	4850%	4850%	9700%	4850%	4850%
Category CT	9800	4900	4900	9800	4900	4900	9800%	4900%	4900%	9800%	4900%	4900%
Category CU	9900	4950	4950	9900	4950	4950	9900%	4950%	4950%	9900%	4950%	4950%
Category CV	10000	5000	5000	10000	5000	5000	10000%	5000%	5000%	10000%	5000%	5000%
Category CW	10100	5050	5050	10100	5050	5050	10100%	5050%	5050%	10100%	5050%	5050%
Category CX	10200	5100	5100	10200	5100	5100	10200%	5100%	5100%	10200%	5100%	5100%
Category CY	10300	5150	5150	10300	5150	5150	10300%	5150%	5150%	10300%	5150%	5150%
Category CZ	10400	5200	5200	10400	5200	5200	10400%	5200%	5200%	10400%	52	